AR and prostate carcinoma: The current strategy used in treating prostate cancer is to block the synthesis of androgen and the androgen receptor, and Kong et al. have found that SeNPs partially inhibit the growth of prostate LNCaP cancer cells through caspase-mediated apoptosis.